Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations

被引：99
|
作者：
Ahn, Inhye E. [1 ]
Tian, Xin [1 ]
Wiestner, Adrian [1 ]
机构：
[1] NHLBI, Bldg 10, Bethesda, MD 20892 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 05期
关键词：
CLL;
D O I：
10.1056/NEJMc2005943
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with chronic lymphocytic leukemia with chromosome 17 abnormalities have a worse prognosis than those without such alterations. In this phase 2 study, patients who received continuous ibrutinib had a durable response that continued after 6.5 years in some patients.
引用
收藏
页码：498 / 500
页数：3
相关论文
共 50 条
  • [31] Clinical Impact of Clonal and Subclonal TP53 Mutations in Chronic Lymphocytic Leukemia
    Bomben, Riccardo
    Rossi, Maria Francesca
    D'Agaro, Tiziana
    Bittolo, Tamara
    Zucchetto, Antonella
    Tissino, Erika
    Pozzo, Federico
    Vit, Filippo
    Bulian, Pietro
    Degan, Massimo
    Zaina, Eva
    Cattarossi, Ilaria
    Nanni, Paola
    Chivilo, Hillarj
    D'Arena, Giovanni Francesco
    Chiarenza, Annalisa
    Santinelli, Enrico
    Zaja, Francesco
    Pozzato, Gabriele
    Di Raimondo, Francesco
    Del Poeta, Giovanni
    Gattei, Valter
    BLOOD, 2018, 132
  • [32] Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
    Rossi, Davide
    Khiabanian, Hossein
    Spina, Valeria
    Ciardullo, Carmela
    Bruscaggin, Alessio
    Fama, Rosella
    Rasi, Silvia
    Monti, Sara
    Deambrogi, Clara
    De Paoli, Lorenzo
    Wang, Jiguang
    Gattei, Valter
    Guarini, Anna
    Foa, Robin
    Rabadan, Raul
    Gaidano, Gianluca
    BLOOD, 2014, 123 (14) : 2139 - 2147
  • [33] Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia with TP53 Mutations
    Hwang, Steven R.
    Wang, Yucai
    Rabe, Kari G.
    He, Rong
    Kenderian, Saad S.
    Muchtar, Eli
    Hampel, Paul J.
    Kay, Neil E.
    Call, Timothy G.
    Koehler, Amber
    Behnken, Amy L.
    Leis, Jose F.
    Braggio, Esteban
    Shi, Min
    Viswanatha, David S.
    Van Dyke, Daniel L.
    Slager, Susan L.
    Parikh, Sameer A.
    Ding, Wei
    BLOOD, 2022, 140 : 12390 - 12392
  • [34] TP53 MUTATIONS ARE INFREQUENT IN NEWLY-DIAGNOSED CHRONIC LYMPHOCYTIC LEUKEMIA
    Murray, F.
    Zainuddin, N.
    Kanduri, M.
    Gunnarsson, R.
    Smedby, K. Ekstrom
    Enblad, G.
    Jurlander, I.
    Juliusson, G.
    Rosenquist, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 39 - 39
  • [35] Clinical Impact Of Small TP53 Mutated Subclones In Chronic Lymphocytic Leukemia
    Rossi, Davide
    Khiabanian, Hossein
    Ciardullo, Carmela
    Spina, Valeria
    Bruscaggin, Alessio
    Fama, Rosella
    Monti, Sara
    Rasi, Silvia
    Wang, Jiguang
    Gattei, Valter
    Guarini, Anna
    FoA, Robin
    Rabadan, Raul
    Gaidano, Gianluca
    BLOOD, 2013, 122 (21)
  • [36] TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia
    Hua-Jie Dong
    Cheng Fang
    Li Wang
    Lei Fan
    Ji Xu
    Jia-Zhu Wu
    Ting-Xun Lu
    Jian-Yong Li
    Wei Xu
    Medical Oncology, 2014, 31
  • [37] TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia
    Dong, Hua-Jie
    Fang, Cheng
    Wang, Li
    Fan, Lei
    Xu, Ji
    Wu, Jia-Zhu
    Lu, Ting-Xun
    Li, Jian-Yong
    Xu, Wei
    MEDICAL ONCOLOGY, 2014, 31 (04)
  • [38] Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia
    te Raa, G. Doreen
    Malcikova, Jitka
    Pospisilova, Sarka
    Trbusek, Martin
    Mraz, Mark
    Le Garff-Tavernier, Maria
    Merle-Beral, Helene
    Lin, Ke
    Pettitt, Andrew R.
    Merkel, Olaf
    Stankovic, Tatjana
    van Oers, Marinus H.
    Eldering, Eric
    Stilgenbauer, Stephan
    Zenz, Thorsten
    Kater, Arnon P.
    LEUKEMIA & LYMPHOMA, 2013, 54 (08) : 1849 - 1853
  • [39] No benefit from adding rituximab to ibrutinib in relapsed or refractory chronic lymphocytic leukemia or 17p deletion/TP53 mutation
    Calleja, Anne
    HEMATOLOGIE, 2019, 25 (03): : 131 - 132
  • [40] TP53 mutation analysis in chronic lymphocytic leukaemia
    Fesus Viktoria
    Marosvari Dora
    Kajtar Bela
    Kiraly Peter Attila
    Demeter Judit
    Gurbity Palfi Timea
    Egyed Miklos
    Plander Mark
    Farkas Peter
    Matrai Zoltan
    Matolcsy Andras
    Bodor Csaba
    ORVOSI HETILAP, 2017, 158 (06) : 220 - 228
12345